Cargando…

Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report

To describe a case of complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis. Case report: Medical/surgical intensive care unit (ICU) of a university teaching hospital. A 62-year-old man presented to a local h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omura, Taku, Watanabe, Eizo, Otsuka, Yasufumi, Yoshida, Yoko, Kato, Hideki, Nangaku, Masaomi, Miyata, Toshiyuki, Oda, Shigeto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	3900
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058839/ https://www.ncbi.nlm.nih.gov/pubmed/27399110 http://dx.doi.org/10.1097/MD.0000000000004104

Ejemplares similares

Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report
por: Abe, Tomohiro, et al.
Publicado: (2017)

Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report
por: Saito, Daiki, et al.
Publicado: (2019)

Eculizumab in chemotherapy-induced thrombotic microangiopathy
por: Schulte-Kemna, Lena, et al.
Publicado: (2020)

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
por: Grall, Maximilien, et al.
Publicado: (2021)

The use of eculizumab in gemcitabine induced thrombotic microangiopathy
por: Krishnappa, Vinod, et al.
Publicado: (2018)

The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
por: Gabr, Jihad Ben, et al.
Publicado: (2020)

Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab
por: Jin, Anna, et al.
Publicado: (2016)

Scleroderma Renal Crisis With Thrombotic Microangiopathy Treated With Eculizumab
por: Saba, Ludovic, et al.
Publicado: (2022)

Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding
por: Fujita, Yoko, et al.
Publicado: (2020)

Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease
por: Chonat, Satheesh, et al.
Publicado: (2020)

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy
por: Gomez-Ganda, Laura, et al.
Publicado: (2021)

Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab
por: Efe, Orhan, et al.
Publicado: (2021)

Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series
por: Vitkauskaitė, Monika, et al.
Publicado: (2022)

Bevacizumab-Associated Thrombotic Microangiopathy Treated with Eculizumab: A Case Report
por: Padilha, Wallace Stwart Carvalho, et al.
Publicado: (2023)

Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report
por: Van den Eeckhaut, Lisa, et al.
Publicado: (2022)

Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura
por: Nakamura, Kensuke, et al.
Publicado: (2016)

Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
por: Gosain, Rahul, et al.
Publicado: (2017)

The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report
por: Bjørkto, Magnus Holter, et al.
Publicado: (2021)

A case report: Hemophagocytic lymphohistiocytosis and thrombotic thrombocytopenic purpura in an otherwise healthy woman
por: Li, Yuanyuan, et al.
Publicado: (2023)

Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome
por: Thomas, Christie P., et al.
Publicado: (2015)

Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab
por: Uriarte, Maite Hurtado, et al.
Publicado: (2018)

Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer
por: Hausberg, Martin, et al.
Publicado: (2019)

A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
por: Wright, Rachael D., et al.
Publicado: (2020)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021)

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT
por: Mizuno, Kana, et al.
Publicado: (2022)

A new strategy of enteral nutrition intervention for ICU patients targeting intestinal flora
por: Guo, Yangyang, et al.
Publicado: (2021)

Clinical characteristics and remission of nine cases with coronavirus disease 2019 infection in Zunyi, Southwest of China: A retrospective study
por: Chen, Hongjun, et al.
Publicado: (2022)

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
por: Lanfranco, Luca, et al.
Publicado: (2017)

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
por: Allinovi, Marco, et al.
Publicado: (2017)

Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report
por: Facchini, Ludovica, et al.
Publicado: (2017)

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy
por: Haninger-Vacariu, Natalja, et al.
Publicado: (2020)

Unique Presentation of Bortezomib-Associated Thrombotic Microangiopathy Responsive to Therapeutic Plasma Exchange and Eculizumab Therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis Treated with Eculizumab: A Case Report
por: Torres, Everardo Arias, et al.
Publicado: (2021)

Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy
por: Sridharan, Meera, et al.
Publicado: (2022)

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
por: Acosta-Medina, Aldo A., et al.
Publicado: (2022)

Effects of early enteral nutrition on T helper lymphocytes of surgical septic patients: A retrospective observational study
por: Sun, Jia-Kui, et al.
Publicado: (2017)

Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis
por: Zhang, Rui, et al.
Publicado: (2021)

Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report
por: Nakamura, Masahiko, et al.
Publicado: (2022)

Effects of intermittent feeding versus continuous feeding on enteral nutrition tolerance in critically ill patients: A protocol for systematic review and meta-analysis
por: Li, Yuanli, et al.
Publicado: (2020)

Thrombotic Microangiopathies
por: Radhi, Mohamed, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9ghg4chitv0i4jrpshik649se9